RETRACTED: Chemotherapy-induced broadly reactive autoantibodies in the treatment of malignancies

RETRACTED ARTICLE

The aim of the study was to evaluate the relationship between chemotherapy and autoimmune reactions in patients with metastatic colorectal cancer. Cancer and autoimmunity are known to be interrelated, but until now it has been unclear to what extent chemotherapy specifically contributes to autoimmune reactions. We studied immunoglobulin M (IgM) levels in response to the administration of various human tissues before and during adjuvant chemotherapy. Patients received seven cycles of chemotherapy with the FOLFIRI plus cetuximab regimen. IgM levels against the tested tissues increased already after the first cycle of chemotherapy and continued to increase during the second and third cycles. Autoimmune responses then began to decrease from the fourth to seventh cycles, but remained elevated from baseline for most of the study tissues. Our results suggest that chemotherapy can induce a wide range of autoimmune reactions. Monitoring self-reactive IgM responses during treatment may help prevent or alleviate side effects associated with autoimmunity.

1. Johnson A.K. Repercussions of occult malignancy – an etiologic basis for rheumatic disease. Med Hypotheses. 2013;80:447-51. https://doi.org/10.1016/j.mehy.2012.12.038

2. Naschitz J.E. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol. 2001;13:62-6. https://doi.org/10.1097/00002281-200101000-00010

3. Chatham M., Niravath P. Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature. Cureus. 2021;13:e20203. https://doi.org/10.7759/cureus.20203

4. Mandal S., Pile K., Chacko R.T., Danda D. Malignancy and autoimmunity: causally or casually related? Int J Rheum Dis. 2014;17:601-5. https://doi.org/10.1111/1756-185X.12536

5. Albert M.L., Darnell R.B. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer. 2004;4:36-44. https://doi.org/10.1038/nrc1255

6. Joseph C.G., Darrah E., Shah A.A. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343:152-7. https://doi.org/10.1126/science.1246886

7. Teng M.W., Smyth M.J. Cancer. Can cancer trigger autoimmunity? Science. 2014;343:147-8. https://doi.org/10.1126/science.1249486

8. De Jonge H., Iamele L., Maggi M., Pessino G., Scotti C. Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues. Cancers (Basel). 2021;13:813. https://doi.org/10.3390/cancers13040813

9. Wilson A.L., Moffitt L.R., Duffield N., Rainczuk A., Jobling T.W., Plebanski M., Stephens A.N. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27:183-192. https://doi.org/10.1158/1055-9965.EPI-17-0752

10. Roney M.SI., Lanagan C., Sheng Y.H. et al. IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread. Clin Transl Immunology. 2021;10:e1330. https://doi.org/10.1002/cti2.1330

11. Ocadlikova D., Lecciso M., Isidori A. et al. Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Front Oncol. 2019;9:1004. https://doi.org/10.3389/fonc.2019.01004

12. Yamada N., Yamasaki K., Yamamoto N., Kuki I., Sakuma H., Hara J. Chemotherapy-induced autoimmune-mediated encephalitis during germinoma treatment. Brain Dev. 2021;43:967-971. https://doi.org/10.1016/j.braindev.2021.05.010

13. Strenger V., Merth G., Lackner H. et al. Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years. Ann Hematol. 2018;97:989-998. https://doi.org/10.1007/s00277-018-3254-4

14. Kim M.J., Ye Y.M., Park H.S., Suh C.H. Chemotherapy-related arthropathy. J Rheumatol. 2006;33:1364-8.

15. Wang L., Wei Y., Fang W., Lu C., Chen J., Cui G., Diao H. Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer. Cell Physiol Biochem. 2017;44:1038-1050. https://doi.org/10.1159/000485404

16. Narang A., Qiao F., Atkinson C., et al. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury, drive secondary injury by activating complement. J Neuroinflammation. 2017;14:120. https://doi.org/10.1186/s12974-017-0894-6

17. Needham E.J., Stoevesandt O., Thelin E.P. et al. Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. J Immunol. 2021;207:90-100. https://doi.org/10.4049/jimmunol.2001309

18. Chakraborty S., Karasu E., Huber-Lang M. Complement After Trauma: Suturing Innate and Adaptive Immunity. Front Immunol. 2018; 9:2050. https://doi.org/10.3389/fimmu.2018.02050

19. Fuentes-Antrás J., Peinado P., Guevara-Hoyer K., Del Arco C.D., Sánchez-Ramón S., Aguado C. Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematol Oncol Stem Cell Ther. 2020;S1658-3876(20)30098-4. https://doi.org/10.1016/j.hemonc.2020.04.006

20. Sotzny F., Filgueiras I.S., Kedor C. et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022;13:981532. https://doi.org/10.3389/fimmu.2022.981532

21. Shanin V.Y. Immunologically substance, process for preparing same, bioprobe, pharmaceutical composition, diagnostics and treatment methods. WO2012053928A1. 2012, EA 018848B1.